Consistently, vital studies have indicated that miR-192-5p plays a role in the resistance of EC and gastric cancer to chemotherapy, which reverses cisplatin resistance by targeting ERCC3 and ERCC4 in gastric cancer lines (Hummel et al., 2014; Xie et al., 2019). Here, ERCC3 is linked to gastric cancer.